Activities

Summary

Within the life sciences industry, paper-based QC Micro laboratory processes can be expensive, error-prone, time and labour-intensive. With the MODA solution, organisations can automate quality control processes for regulated manufacturing and quickly advance their "Green: initiatives.

Profile

More science. Less Paper.™

The MODA™ solution, a paperless QC micro data management software and part of Lonza’s Rapid Testing Solutions (RTS), delivers a comprehensive informatics platform that automates quality control (QC) processes for all regulated manufacturing in the Life Sciences industry. As a user of the MODA™ solution, Lonza has direct experience with its value – providing improved decision making, regulatory compliance, and productivity across our own global manufacturing facilities. The MODA™ solution delivers mobile data acquisition, visualization mapping, and on-demand analytics.


Mobile data acquisition platform

The MODA™ solution integrates with Laboratory Information Management Systems (LIMS) to bridge the communication gap between QC and production. Components include:

By combining, mobile data acquisition, flexible workflow, device integration, and advanced analytics, the MODA™ solution delivers efficiencies across your organisation.

QC departments are able to:


For questions or to schedule a personal consultation on the MODA™ solution, contact:


Europe

Ms Sinead Cowman

Product Support Specialist

Lonza Verviers

Parc Industriel de Petit-Rechain

Veriviers, Belgium B-4800

Tel: +32 8732 1611

Email: sinead.cowman@lonza.com


US

Mr. Robert Lutskus

Sr. Product Strategist

Lonza Wayne

1255 Drummers Lane

Wayne, PA 19087

Tel: + 1 201-315-9534

Email: Robert.lutskus@lonza.com


About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products.

In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2010, the company had sales of CHF 2.680 billion.